e-SPACE Cardio-Renal-Metabolic 2023

Published: 25 March 2023

  • Views:

    Views Icon 12811
  • Likes:

    Heart Icon 7
  • episode_image
    58m 8s
    Part 1 | Session 1 Plenary session 1 – HFpEF Andrew JS Coats, Giuseppe Rosano, Eberhard Standl, María José Soler, Stefan Anker
Average (ratings)
No ratings
Your rating


e-SPACE Cardio-Renal-Metabolic 2023 was the third edition of the annual global online conference that explores how leading experts, in cardiology, nephrology, and diabetology, are treating the interrelated diseases.


Course leadership Prof Stefan Anker (Berlin, DE), Dr Javed Butler (Texas, US), Prof Antonio Ceriello (Milan, IT), Prof Tara I Chang (California, US), Prof Ian de Boer (Washington, US), Prof Peter Rossing (Copenhagen, DK) and Prof Shelley Zieroth (Winnipeg, CA) lead an interactive programme of plenary sessions, meet the expert, case discussions and satellite symposium sessions focusing on the patient journey.


For the first time, e-SPACE Cardio-Renal-Metabolic 2023 brought together TMA’s mandate for the delivery of continuing professional development to healthcare professionals to achieve concordance with appropriate treatment plans, alongside KDIGO's mission to improve the care and outcomes of patients with kidney disease worldwide through the development and implementation of global clinical practice guidelines, with Radcliffe Cardiology’s goal to deliver cardiovascular knowledge to best support cardiovascular communities transform theory into practice.


e-SPACE Cardio-Renal-Metabolic 2023 would like to thank the following sponsors:

Learning Objectives

  • Review the burden of diabetes, kidney disease and heart failure including morbidity, excess mortality, and reduced quality of life affecting individuals around the world
  • Describe the complexity and interlink between the three conditions
  • Discuss existing guidelines and best approaches for screening patients
  • Review evidence-based management strategies for diabetes, cardiovascular disease, heart failure, kidney disease & obesity including SLGT2i, GLP-1RA, new non-steroidal mineralocorticoid receptor antagonists and other emerging therapies
  • Foster cross-collaboration between other cardiorenal / metabolic specialists and primary care physicians and allied health care professionals in order to improve patients outcomes

Target Audience

  • Cardiologists
  • Nephrologists
  • Diabetologists
  • General Practitioners (GPs)
  • HF Specialists
  • Nurses, Pharmacists, and other Allied Healthcare Professionals

More from this programme

Faculty Biographies

John J Atherton

John J Atherton

Director of Cardiology

Dr John Atherton is Director of Cardiology, Royal Brisbane and Women’s Hospital, Associate Professor, University of Queensland, and Adjunct Professor, Queensland University of Technology.

Dr Atherton was on the board of the Cardiac Society of Australia and New Zealand (CSANZ, 2009–2015) and chairs the CSANZ Professional Ethics Standards Committee. He previously chaired the Asia-Pacific Acute Decompensated Heart Failure Registry Scientific Advisory Committee and the CSANZ Heart Failure Council. Dr Atherton is an appointed member of the Australian Government Medical Services Advisory Committee and provides advice to Government on public funding arrangements through Medicare.

Dr Atherton is Associate Editor, Heart Lung and Circulation, and sits on the editorial board for Cardiac Failure Review. His research interests include screening for pre-symptomatic heart disease and heart failure disease management. His contributions to service enhancement…

View full profile
Petar M Seferovic

Petar M Seferovic

Professor of Internal Medicine

Prof Petar Seferović is a Professor of Internal Medicine at Belgrade University, Belgrade, RS.

In 1990, he got his PhD from the School of Medicine, University of Belgrade.

Prof Seferović is the past President of the Heart failure Association of the ESC and has co-authored over 800 publications.


View full profile
John GF Cleland

John GF Cleland

Professor of Cardiology

Prof John Cleland is a Professor of Cardiology at University of Glasgow, Glasgow, UK.

In 1977, he qualified from the University of Glasgow, completed training at St. Mary's & Hammersmith Hospitals (London) and was awarded a Senior Fellowship by the British Heart Foundation.

His main interests include heart failure, extending from epidemiology & prevention, to Phase II-IV trials and guidelines. 

He founded the European Journal of Heart Failure and is Past-Chair of the ESC Working Group on heart failure and British Society for Heart Failure.




View full profile
Michael Böhm

Michael Böhm

Director Internal Medicine Clinic III, Angiology and Intensive Care Medicine

Dr Michael Böhm performed his medical training at the Medical School of Hannover in Germany. Residency in Internal Medicine and fellowships in Cardiology at the Ludwig Maximilians-Unversity in Munich/Germany at the Klinikum Großhadern; Heisenberg Graduate of the Deutsche Forschungsgemeinschaft; Assistant and Associate Dr of Internal Medicine and Cardiology at the Universität zu Köln in Germany.

Dr Böhm is Director of the Klinik für Innere Medizin III and Chief of Cardiology at the University of the Saarland in Homburg/Saar in Germany. Dr Böhm's special interest includes pathophysiology and therapy of heart failure. Particular, he is involved in studies on signal transduction in the failing heart and in vascular biology. Dr Böhm has been the principal investigator in several international multicenter studies. He has written more than 350 original papers, book chapters and review articles. He has obtained several awards of scientific societies. Dr Böhm is a reviewer for…

View full profile
Meg Jardine

Meg Jardine

Director of the NHMRC Clinical Trials Centre

Prof Meg Jardine is Director of the NHMRC Clinical Trials Centre at University of Sydney, Camperdown, AU.

She is a member of the International Society of Nephrology Executive Committee (2023 – 2025), an Executive Committee member of the international nephrology guidelines body, KDIGO, and has contributed to Australian CARI guideline development.

Prof Jardine's research focusses on reducing the progression and complications of non-communicable diseases, particularly kidney disease, diabetes and cardiovascular disease, through randomised trials and epidemiological analyses.

View full profile
Daniël van Raalte

Daniël van Raalte

Professor of Medicine

Dr Daniël van Raalte is a Professor of Medicine at Amsterdam UMC, Amsterdam, NL.

His particular interest is in Clinical Diabetology and his top areas of expertise include Type 2 Diabetes (T2D), Diabetic Nephropathy, Wilson Disease, and Osmotic Diuresis.

View full profile


You must be to comment. If you are not registered, you can register here.